Karin S Coyne1, Louis S Matza, Christine L Thompson. 1. MEDTAP International, Inc., Center for Health Outcomes Research, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA. Coyne@medtap.com
Abstract
PURPOSE: The purpose of this study was to examine the responsiveness of the Overactive Bladder questionnaire (OAB-q) during anti-muscarinic treatment. METHODS: OAB patients were treated with tolterodine ER 4 mg/day for 12 weeks. The OAB-q and 3-day micturition diaries were collected at baseline, 4, and 12 weeks. The patients' and physicians' perceptions of treatment benefit were assessed at 4 and 12 weeks. Responsiveness of the OAB-q was examined with effect sizes and comparisons to other measures using ANOVAs, t-tests, and correlations. RESULTS: A total of 865 patients completed the 12-week study (mean age 61 years; 73% female; 89% Caucasian). From baseline to 4 weeks, significant improvements (p < 0.0001) occurred in all OAB-q subscales, which were maintained through week 12. The OAB-q was highly responsive with subscale effect sizes ranging from 0.44 (social interaction) to 1.2 (symptom bother). Significant score changes in all OAB-q subscales (p < 0.05) were associated with reductions of > or = 3 urgency episodes, > or = 3 micturitions, or > or = 1 incontinence episode per day. Improvements in OAB-q scales were associated with changes in patient and physician perceptions of treatment benefit. CONCLUSIONS: The OAB-q was highly responsive and demonstrated responsiveness to reductions in urinary urgency, frequency, and incontinence during antimuscarinic treatment of OAB. The OAB-q appears to be a useful outcome measure for treatments of OAB.
PURPOSE: The purpose of this study was to examine the responsiveness of the Overactive Bladder questionnaire (OAB-q) during anti-muscarinic treatment. METHODS:OABpatients were treated with tolterodine ER 4 mg/day for 12 weeks. The OAB-q and 3-day micturition diaries were collected at baseline, 4, and 12 weeks. The patients' and physicians' perceptions of treatment benefit were assessed at 4 and 12 weeks. Responsiveness of the OAB-q was examined with effect sizes and comparisons to other measures using ANOVAs, t-tests, and correlations. RESULTS: A total of 865 patients completed the 12-week study (mean age 61 years; 73% female; 89% Caucasian). From baseline to 4 weeks, significant improvements (p < 0.0001) occurred in all OAB-q subscales, which were maintained through week 12. The OAB-q was highly responsive with subscale effect sizes ranging from 0.44 (social interaction) to 1.2 (symptom bother). Significant score changes in all OAB-q subscales (p < 0.05) were associated with reductions of > or = 3 urgency episodes, > or = 3 micturitions, or > or = 1 incontinence episode per day. Improvements in OAB-q scales were associated with changes in patient and physician perceptions of treatment benefit. CONCLUSIONS: The OAB-q was highly responsive and demonstrated responsiveness to reductions in urinary urgency, frequency, and incontinence during antimuscarinic treatment of OAB. The OAB-q appears to be a useful outcome measure for treatments of OAB.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein Journal: Am J Obstet Gynecol Date: 2002-07 Impact factor: 8.661
Authors: Mirjam A G Sprangers; Carol M Moinpour; Timothy J Moynihan; Donald L Patrick; Dennis A Revicki Journal: Mayo Clin Proc Date: 2002-06 Impact factor: 7.616
Authors: W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein Journal: World J Urol Date: 2002-11-15 Impact factor: 4.226
Authors: Alayne D Markland; Vin Tangpricha; T Mark Beasley; Camille P Vaughan; Holly E Richter; Kathryn L Burgio; Patricia S Goode Journal: J Am Geriatr Soc Date: 2018-12-21 Impact factor: 5.562
Authors: Keisha Y Dyer; Yan Xu; Linda Brubaker; Ingrid Nygaard; Alayne Markland; David Rahn; Toby C Chai; Ann Stoddard; Emily Lukacz Journal: Neurourol Urodyn Date: 2011-05-11 Impact factor: 2.696
Authors: Zalmai Hakimi; Mike Herdman; Marco Pavesi; Nancy Devlin; Jameel Nazir; Chris Hoyle; Isaac A O Odeyemi Journal: Qual Life Res Date: 2016-11-28 Impact factor: 4.147
Authors: Alexis A Dieter; Autumn L Edenfield; Alison C Weidner; Pamela J Levin; Nazema Y Siddiqui Journal: Int Urogynecol J Date: 2014-05-09 Impact factor: 2.894